BR112023020057A2 - Tratamento de dor e distúrbios inflamatórios - Google Patents
Tratamento de dor e distúrbios inflamatóriosInfo
- Publication number
- BR112023020057A2 BR112023020057A2 BR112023020057A BR112023020057A BR112023020057A2 BR 112023020057 A2 BR112023020057 A2 BR 112023020057A2 BR 112023020057 A BR112023020057 A BR 112023020057A BR 112023020057 A BR112023020057 A BR 112023020057A BR 112023020057 A2 BR112023020057 A2 BR 112023020057A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- pain
- chain
- clostridial neurotoxin
- domain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW110111559A TW202237176A (zh) | 2021-03-30 | 2021-03-30 | 疼痛及發炎性失調之治療 |
| PCT/GB2021/050783 WO2022208039A1 (en) | 2021-03-30 | 2021-03-30 | Catalytically inactive clostridial neurotoxins for the treatment of pain & inflammatory disorders |
| PCT/GB2022/050807 WO2022208091A1 (en) | 2021-03-30 | 2022-03-30 | Treatment of pain & inflammatory disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023020057A2 true BR112023020057A2 (pt) | 2024-03-12 |
Family
ID=83458127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023020057A BR112023020057A2 (pt) | 2021-03-30 | 2022-03-30 | Tratamento de dor e distúrbios inflamatórios |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250195626A1 (https=) |
| EP (1) | EP4313120A1 (https=) |
| JP (1) | JP2024513191A (https=) |
| KR (1) | KR20230163470A (https=) |
| AU (1) | AU2022247196A1 (https=) |
| BR (1) | BR112023020057A2 (https=) |
| CA (1) | CA3213914A1 (https=) |
| WO (1) | WO2022208091A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023089343A1 (en) * | 2021-11-22 | 2023-05-25 | Ipsen Biopharm Limited | Treatment of pain |
| JP2025534349A (ja) * | 2022-09-30 | 2025-10-15 | イプセン バイオファーム リミテッド | 膀胱痛症候群の治療 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| IL99552A0 (en) | 1990-09-28 | 1992-08-18 | Ixsys Inc | Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof |
| WO1993015766A1 (en) | 1992-02-10 | 1993-08-19 | Seragen, Inc. | Desensitization to specific allergens |
| GB9305735D0 (en) | 1993-03-19 | 1993-05-05 | North John R | Novel agent for controlling cell activity |
| GB9508204D0 (en) | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
| US7192596B2 (en) | 1996-08-23 | 2007-03-20 | The Health Protection Agency Ipsen Limited | Recombinant toxin fragments |
| GB9617671D0 (en) | 1996-08-23 | 1996-10-02 | Microbiological Res Authority | Recombinant toxin fragments |
| GB9721189D0 (en) | 1997-10-08 | 1997-12-03 | Speywood Lab The Limited | Analgesic conjugates |
| CN1241945C (zh) | 1998-05-13 | 2006-02-15 | 拜欧特康生化技术开发和咨询有限公司 | 用于抑制肥大细胞脱粒的杂合蛋白质及其用途 |
| DE69910216T2 (de) | 1998-07-22 | 2004-02-19 | Osprey Pharmaceuticals Ltd., Calgary | Konjugate zur behandlung von entzündungskrankheiten und von assozierter gewebeschädigung |
| GB9818548D0 (en) | 1998-08-25 | 1998-10-21 | Microbiological Res Authority | Treatment of mucas hypersecretion |
| US6776990B2 (en) | 1999-04-08 | 2004-08-17 | Allergan, Inc. | Methods and compositions for the treatment of pancreatitis |
| US6358697B2 (en) | 1999-04-21 | 2002-03-19 | Children's Hospital Medical Center | Intracellular pharmaceutical targeting |
| ATE348178T1 (de) | 1999-08-25 | 2007-01-15 | Allergan Inc | Aktivierbare rekombinante neurotoxine |
| GB9922554D0 (en) | 1999-09-23 | 1999-11-24 | Microbiological Res Authority | Inhibition of secretion from non-neuronal cells |
| DE102004043009A1 (de) | 2004-09-06 | 2006-03-23 | Toxogen Gmbh | Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen |
| AU2005311086B2 (en) | 2004-12-01 | 2012-03-29 | Allergan, Inc. | Fusion proteins |
| DE102005019302A1 (de) | 2005-04-26 | 2006-11-16 | Toxogen Gmbh | Carrier zum Targeting von Nervenzellen |
| ATE518882T1 (de) | 2005-09-19 | 2011-08-15 | Allergan Inc | Mit clostridientoxin aktivierbare clostridientoxine |
| WO2008008805A2 (en) | 2006-07-11 | 2008-01-17 | Allergan, Inc. | Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells |
| AU2007272515B2 (en) | 2006-07-11 | 2013-09-26 | Allergan, Inc. | Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells |
| UA116985C2 (uk) | 2012-05-30 | 2018-06-11 | Президент Енд Феллоуз Оф Гарвард Колледж | Рекомбінантний ботулінічний нейротоксин |
| GB201312317D0 (en) | 2013-07-09 | 2013-08-21 | Syntaxin Ltd | Cationic neurotoxins |
| WO2016110662A1 (en) | 2015-01-09 | 2016-07-14 | Ipsen Bioinnovation Limited | Cationic neurotoxins |
| PT3274364T (pt) | 2015-03-26 | 2021-11-05 | Harvard College | Neurotoxina botulínica manipulada |
| GB201517450D0 (en) * | 2015-10-02 | 2015-11-18 | Ipsen Biopharm Ltd | Method |
| GB201607901D0 (en) | 2016-05-05 | 2016-06-22 | Ipsen Biopharm Ltd | Chimeric neurotoxins |
| EP3481852B1 (en) | 2016-07-08 | 2022-12-07 | Children's Medical Center Corporation | A novel botulinum neurotoxin and its derivatives |
| TWI822723B (zh) | 2018-01-29 | 2023-11-21 | 英商艾普森生物製藥有限公司 | 非神經元性 SNARE 裂解的肉毒桿菌神經毒素、裂解 hSNAP-23 之活體外方法、及經修飾 BoNT/A L 鏈蛋白酶之用途 |
| WO2019152380A1 (en) * | 2018-01-30 | 2019-08-08 | Children's Medical Center Corporation | Production of botulinum neurotoxins using bacillus systems |
| GB201815817D0 (en) | 2018-09-28 | 2018-11-14 | Ispen Biopharm Ltd | Clostridial neurotoxins comprising and exogenous activation loop |
| US20220220466A1 (en) * | 2019-04-17 | 2022-07-14 | Children's Medical Center Corporation | Catalytically inactive botulinum neurotoxin-like toxins and uses thereof |
-
2022
- 2022-03-30 JP JP2023559999A patent/JP2024513191A/ja active Pending
- 2022-03-30 EP EP22716099.1A patent/EP4313120A1/en active Pending
- 2022-03-30 AU AU2022247196A patent/AU2022247196A1/en active Pending
- 2022-03-30 KR KR1020237036646A patent/KR20230163470A/ko active Pending
- 2022-03-30 WO PCT/GB2022/050807 patent/WO2022208091A1/en not_active Ceased
- 2022-03-30 US US18/552,788 patent/US20250195626A1/en active Pending
- 2022-03-30 BR BR112023020057A patent/BR112023020057A2/pt unknown
- 2022-03-30 CA CA3213914A patent/CA3213914A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250195626A1 (en) | 2025-06-19 |
| CA3213914A1 (en) | 2022-10-06 |
| JP2024513191A (ja) | 2024-03-22 |
| AU2022247196A9 (en) | 2024-02-22 |
| EP4313120A1 (en) | 2024-02-07 |
| KR20230163470A (ko) | 2023-11-30 |
| WO2022208091A1 (en) | 2022-10-06 |
| AU2022247196A1 (en) | 2023-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023020057A2 (pt) | Tratamento de dor e distúrbios inflamatórios | |
| BR112022017930A2 (pt) | Anticorpos anticoronavírus e métodos de uso | |
| BR112022014623A2 (pt) | Anticorpos e proteínas de fusão que se ligam a ccr8 e usos dos mesmos | |
| BRPI0509207A (pt) | moduladores canabinóides de tetraidro-indazol | |
| BR112022008858A2 (pt) | Composto, composição farmacêutica e métodos para inibir sos1 em um sujeito, para inibir a interação de sos1 e uma proteína, para tratar ou prevenir uma doença e para tratar ou prevenir câncer | |
| BR112013007314A2 (pt) | anticorpos anti-cd48 e seus usos | |
| BR112022012969A2 (pt) | Moléculas de ligação, molécula de ácido nucleico isolada, vetor, célula hospedeira, composição farmacêutica, usos da molécula de ligação, métodos para produzir a molécula de ligação, tratar um indivíduo com câncer e suprarregular ou prolongar a atividade de células t citotóxicas em um indivíduo com câncer | |
| BR112021016272A2 (pt) | Receptores de antígeno quimérico anti-dll3 humanizados e usos dos mesmos | |
| BR112019005895A2 (pt) | moléculas de ligação que modulam uma atividade biológica expressa por uma célula | |
| BRPI0417493B8 (pt) | uso de uma toxina botulínica para tratamento de distúrbios da pele | |
| CL2007003005A1 (es) | Compuestos derivados de [1,6]-naftiridinona, moduladores de la actividad cinasa; composicion farmaceutica que los comprende; y su uso para tratar trastornos proliferativos, inflamatorios, autoinmune, del sistema nervioso central, entre otros. | |
| AR080685A1 (es) | Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf) | |
| BR112019005139A2 (pt) | anticorpos anti-il-33 e usos dos mesmos | |
| NO20084792L (no) | Substituerte imidazol-4-karboksamider som kolecystokinin-1-reseptormodulatorer | |
| Li et al. | A multi‐center comparative efficacy and safety study of two different hyaluronic acid fillers for treatment of nasolabial folds in a Chinese population | |
| BR112022013780A2 (pt) | Moléculas de anticorpo para c5ar1 e usos das mesmas | |
| BR112023018473A2 (pt) | Neurotoxinas clostridiais cataliticamente inativas para o tratamento de dor e distúrbios inflamatórios | |
| BR112023025528A2 (pt) | Peptídeos grampeados e métodos destes | |
| BR112022007851A2 (pt) | Anticorpo de domínio único anti-il-4r e uso do mesmo | |
| NO20075695L (no) | Fremgangsmate til a behandle eller forhindre type-2 diabetes | |
| BR112023024465A2 (pt) | Usos de um modulador de somatostatina para o tratamento de doença | |
| BRPI0414174A (pt) | moléculas de ligação nogo-a e o uso farmacêutico das mesmas | |
| PH12023550198A1 (en) | Antibody molecules to april and uses thereof | |
| BR112022026747A2 (pt) | Métodos de tratamento do distúrbio do espectro da neuromielite óptica | |
| Mahmoudi et al. | Comparing the neuropsychological features in preschool children with and without developmental coordination disorder (DCD) |